TY  - BOOK
AU  - Böck,Desirée
AU  - Rothgangl,Tanja
AU  - Villiger,Lukas
AU  - Schmidheini,Lukas
AU  - Matsushita,Mai
AU  - Mathis,Nicolas
AU  - Ioannidi,Eleonora
AU  - Rimann,Nicole
AU  - Grisch-Chan,Hiu Man
AU  - Kreutzer,Susanne
AU  - Kontarakis,Zacharias
AU  - Kopf,Manfred
AU  - Thöny,Beat
AU  - Schwank,Gerald
TI  - In vivo prime editing of a metabolic liver disease in mice
PY  - 2022///-03-16
KW  - Text
KW  - local
N1  - /pmc/articles/PMC7614134; /pubmed/35294257
N2  - Prime editing is a highly versatile CRISPR-based genome editing technology that works without DNA double-strand break formation. Despite rapid technological advances, in vivo application for the treatment of genetic diseases remains challenging. Here, we developed a size-reduced SpCas9 prime editor (PE) lacking the RNaseH domain (PE2(ΔRnH)) and an intein-split construct (PE2 p.1153) for adeno-associated virus (AAV)-mediated delivery into the liver. Editing efficiencies reached 15% at the Dnmt1 locus, and were further elevated to 58% by delivering unsplit PE2(ΔRnH) via human adenoviral vector 5 (AdV). To provide proof-of-concept for correcting a genetic liver disease, we next employed the AdV approach for repairing the disease-causing Pah(enu2) mutation in a mouse model of phenylketonuria (PKU) via prime editing. Average correction efficiencies of 11.1% (up to 17.4%) in neonates led to therapeutic reduction of blood phenylalanine (L-Phe), without inducing detectable off-target mutations or prolonged liver inflammation. Although the current in vivo prime editing approach for PKU has limitations for clinical application due to the requirement of high vector doses (7×10(14) vg/kg) and the induction of immune responses to the vector and the PE, further development of the technology may lead to curative therapies for PKU and other genetic liver diseases
UR  - http://dx.doi.org/10.1126/scitranslmed.abl9238
ER  -